FilingSEC EDGAR8-K
Kairos Pharma Reports Positive Phase 2 Interim Data for Prostate Cancer
· SEC accepted
StagePhase 2
Filing content
The company reported statistically significant interim results showing a median progression-free survival of 17.7 months for the combination of ENV-105 and apalutamide compared to 2 months for apalutamide alone.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…